Supplementary Material for: The Effects of Immune Checkpoint Inhibitors on Hidradenitis Su

13 patient cases from 5 publications detail the relationship between immune checkpoint inhibitor cancer therapy and the skin disease hidradenitis suppurativa. This 84.6 KB document, authored by figshare admin karger and updated in April 2026, compiles findings on timing, clinical features, and outcomes. The review suggests these therapies may precipitate new-onset HS or exacerbate pre-existing disease.

Use Cases

• Summarizing clinical evidence on drug-induced skin conditions based on the review's case compilation.
• Analyzing treatment outcomes for HS flares based on the described patient management approaches.
• Identifying temporal patterns of HS onset relative to ICI therapy based on the reported 2-4 month timeframe.

Strengths

• Includes specific patient counts and percentages (e.g., 13 patients, 46.2% on pembrolizumab).
• Follows a structured review methodology (PRISMA guidelines).
• Provides clear temporal data (HS onset within 2-4 months of ICI initiation).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Based on a small sample of 13 patients from only 5 publications.

Provenance

Source

figshare admin karger

Collection Method

Scoping review conducted according to PRISMA guidelines, with studies identified via PubMed and MEDLINE.

Time Range

The review's publication date is implied by the 2026 update, but the temporal coverage of the included studies is not specified.

Freshness

Last updated 2026-04 09:55:12; freshness should be verified.

Geography

null